PureTech Health (PRTC)
(Delayed Data from NSDQ)
$20.69 USD
+0.65 (3.24%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $20.70 +0.01 (0.05%) 7:28 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRTC 20.69 +0.65(3.24%)
Will PRTC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRTC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRTC
PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable
Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround
PRTC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PRTC
IN BRIEF: PureTech's Vor in promising findings in cancer trial
LONDON MARKET MIDDAY: FTSE 100 slips as market stays locked on US jobs
LONDON MARKET OPEN: Stocks stay red as investors prep for US jobs
LONDON BRIEFING: Stocks seen red as eurozone GDP looms
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies